Rx-to-OTC Switch Management Issues
Where
to find more information on Rx-to-OTC Switches
|
|
|
|
Switch Forecast | Switch Scene |
| Dec 98/
Jan‘99 |
|
|
Three Key Questions for the Future of Switch – PLUS… 1989-1998 SWITCHÒ Milestones | SPECIAL
REPORT: All the Major Switches of 1998.
SWITCHÒ 1998 Index |
| Feb ‘99 |
|
|
Who Stole the Switches… and How Can We Get Them Back? | PART ONE - Canada
OTC 1998: Evolving Slowly Regulatory, Distribution
& Exclusivity Issues.
SPECIAL REPORT: A History of Canadian Switches. |
| Mar ‘99 |
|
|
SPECIAL
ISSUE – DSHEA Revisited.
The Evolution of Self-Medication: DSHEA is Only Part of the Story. |
SPECIAL
REPORT: Assessing OTCness of Switch Candidates
for Chronic and/or Recurrent Illness
SWITCHÒ Country Update – US, Canada, Germany, France |
| Apr ‘99 |
|
|
PART TWO – Canada OTC 1998: Finally, the Switch Opportunities May be Opening Up DTC & Dual Status May be Close | Rx Direct-to-Consumer Advertising
is Going to Spread to Other Countries. It Will Change Your Market.
SPECIAL REPORT: Could There be Almost C$1 Billion Suitable for Dual Status in Canada before 2002? |
| May ‘99 |
|
|
A SWITCHÒ
LEGISLATIVE PROPOSAL:
A Win-Win Idea for All. OTC Switch Monitoring and Compliance Research Should Qualify for 1) a 3 Year period of market Exclusivity Plus 2) Access to the Monograph System |
SWITCHÒ
NOTABLES: Belgian, S. Korean & UK Switch
Situations.
SPECIAL REPORT: Answering These Questions Could Earn You Market Exclusivity. |
| Jun/
Jul ‘99 |
|
|
SPECIAL
ISSUE:
FIFTH ANNIVERSARY OF SWITCHÒ Outsourcing Will Grow Dramatically in the Area of Switch. Are You Prepared? |
SWITCHÒ
Issues: The Value of an Independent Opinion
and Opportunities to Professionally Model Switch Scenarios
SWITCHÒ Publisher’s Report: 1999 Progress & Milestones such as Recommendations to Expand Waxman-Hatch. |
| Aug ‘99 |
|
|
ON-LINE Pharmacies: Internet Pharmacies Increase in Importance While Local Pharmacy/Pharmacist Prospects Dim | The Recent US Switch Summit
Was a Success. Will it Pay Long Term Dividends?
SWITCHÒ Issues: The Value of an Independent Opinion and Professionally Modeled Switch Scenarios. SPECIAL REPORT: 1984-1999 – What Switched and Did Not Switch in the US. |
| Sept ‘99 |
|
|
PART ONE: EUROPEAN FOCUS – Disappointing Growth Will Continue Unless Multinationals Unite and Sell Change Aggressively. | Switch
Notables: From Japan, France and Sweden.
SPECIAL REPORT: The Ten (10) Major Inhibitors to OTC Growth in Europe. SWITCHÒ Issues: The Value of an Independent Opinion and Professionally Modeled Switch Scenarios. |
| Oct ‘99 |
|
|
PART TWO: EUROPEAN FOCUS – R+D is Critical to the Future of Switch. Happily, It Has Never been More Intense. | Reimbursement Battles on Flue
Products Miss the Point.
TWO PAGE SPECIAL REPORT: Top 35 US & European Pharmaceutical Company Sales and R+D Ratios. SWITCHÒ Issues: The Value of an Independent Opinion and Professionally Modeled Switch Scenarios. |
| Nov ‘99 |
|
|
Pharma Merger Mania Continues 1) Is It Mostly
Driven by the Increasing Cost for Developing New & Successful drugs, Really? 2) Does the "New Science" Affect Future Switches? 3) Are the Top 35 Rx Sellers Still the Best Switch Opportunities? |
The Once Placid Top 25 Selling Rx Drugs: Future Turbulence Bodes Well for Switches
TWO-PAGE SPECIAL REPORT: The Top Top 35 Selling Rx Drugs (1995-1998 and 2002) and Their Chances of Switching. |
For further information on subscribing to SWITCH®.
Francesco International Tel 1-973-761-5566, Fax 1-973-761-6996, Email Franint